Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - September 15, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis of the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML EMA Recommends Extension of Therapeutic Indications for Teclistamab MOST POPULAR The long road to targeting the holy grail of the immune... November 9, 2020 ScottishPower supports vital research into air pollution and cancer November 24, 2022 Addressing the Barriers to Minority Participation in Cancer Clinical Trials December 21, 2021 Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 Load more HOT NEWS How to Spot Suspicious Herb and Supplement Claims During Cancer Veteran Avoided The Barber For 6 Years After He Left The... The ‘major conditions strategy’: will ministers fail to give cancer the... Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer
